Polaris Oncology Survivor Transition (POST) System

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AG047013-01
Agency Tracking Number: R43AG047013
Amount: $163,134.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NIA
Solicitation Number: PA12-088
Small Business Information
2501 Crosspark Road, Room B126-MTF, Coralville, IA, 52241-
DUNS: 602743903
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (319) 335-1467
Business Contact
Phone: (319) 665-2005
Email: jneighbors@terpenoidtherapeutics.co
Research Institution
DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated bone resorption in comparison to current standard-of-care agents. We have developed a group of proprietary bisphosphonates containing isoprene substructures that demonstrate highly potent and specific GGSI activity in vitro. These compounds do not contain the hydroxyl group or the nitrogen substructure of thecurrent bisphosphonates, which are used clinically. Our GGSIs represent a significant advance in bisphosphonate development in that they target a downstream enzyme relative to the clinical bisphosphonates. We feel that further development of our novel GGSIs for the treatment of osteoporosis is warranted based on the strength of our preliminary studies and the ongoing need for additional treatments for this disease which represents a significant and growing public health problem. Indeed, it is estimated thatby 2025 osteoporosis will result in 25 billion worth of health costs each year. Here we propose SBIR Phase I studies to prove the feasibility of GGSIs in osteoporosis in a commonly used rat model of the disease. The feasibility studies described in thisproposal provide a streamlined approach towards identification of the most active GGSI towards bone resorption from our library using in vitro models, and transition of these active compounds into an in vivo model of bone resorption. In specific aim one we will use cell based models to prioritize our compounds based on osteoclast resorption activity and inhibition of osteoblast apoptosis. Then in specific aim two we will use the highest priority compound in an ovariectomized rat model of osteoporosis and correlate the in vitro data to in vivo measurements of bone strength, biomarkers of mechanism engagement, biomarkers of bone resorption, and ex vivo markers of osteoblast apoptosis. Together these aims will provide us with a go or no-go decision for more elaborate IND enabling studies. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The International Osteoporosis Foundation (IOF) estimates that in 2009 there were approximately 75 million people affected by osteoporosis in the U.S., Europe, and Japan (www.iofbonehealth.org). While much progress has been made in detection and treatment of osteoporosis, bone fractures remain a significant barrier to quality of life and overall survival. In this proposal we advocate developing drugs based on inhibiting an unexploited biological process (protein geranylgeranylation) that is known to be important to processes in osteoporosis including osteoclast-mediated bone resorption. Development of new targeted therapies for bone resorption could have a great impacton this patient population.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government